Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H17ClN2O5 |
| Molecular Weight | 388.802 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(=O)C1=NOC(=C1C2=CC=C(OC)C=C2)C3=C(O)C=C(O)C(Cl)=C3
InChI
InChIKey=JXPCDMPJCKNLBY-UHFFFAOYSA-N
InChI=1S/C19H17ClN2O5/c1-3-21-19(25)17-16(10-4-6-11(26-2)7-5-10)18(27-22-17)12-8-13(20)15(24)9-14(12)23/h4-9,23-24H,3H2,1-2H3,(H,21,25)
| Molecular Formula | C19H17ClN2O5 |
| Molecular Weight | 388.802 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/19244114 | https://www.ncbi.nlm.nih.gov/pubmed/24292262
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/19244114 | https://www.ncbi.nlm.nih.gov/pubmed/24292262
VER-50589 is an isoxazole compound that inhibits a heat shock protein Hsp90. Mean cellular antiproliferative GI(50) value for VER-50589 for a human cancer cell line panel were 78 nM/L, showing a 9-fold potency gain for the isoxazole. VER-50589 shows favorable pharmacokinetics and impairs tumor growth (colon cancer) in animal model. Glioblastoma cells do not acquire resistance to VER-50589 and resistance to other Hsp90 inhibitors does not produce cross-resistance to VER-50589.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation. | 2017-03 |
|
| Minocycline accelerates hypoxia-inducible factor-1 alpha degradation and inhibits hypoxia-induced neovasculogenesis through prolyl hydroxylase, von Hippel-Lindau-dependent pathway. | 2014-03 |
|
| Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. | 2009-03-01 |
|
| 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. | 2008-01-24 |
|
| Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. | 2007-04 |
Sample Use Guides
VER-50589 inhibited HUVEC proliferation with GI50 values of 19 nM/L, respectively. The nontumorigenic
human breast (MCF10a) and prostate (PNT2) epithelial cells exhibited higher GI50 values for VER-
50589 when compared with their respective mean GI50 (330 nM/l and 179.5 nM/l respectively) values against cancer cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 06:40:35 GMT 2025
by
admin
on
Wed Apr 02 06:40:35 GMT 2025
|
| Record UNII |
H4E4ND635H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
135446210
Created by
admin on Wed Apr 02 06:40:35 GMT 2025 , Edited by admin on Wed Apr 02 06:40:35 GMT 2025
|
PRIMARY | |||
|
747413-08-7
Created by
admin on Wed Apr 02 06:40:35 GMT 2025 , Edited by admin on Wed Apr 02 06:40:35 GMT 2025
|
PRIMARY | |||
|
H4E4ND635H
Created by
admin on Wed Apr 02 06:40:35 GMT 2025 , Edited by admin on Wed Apr 02 06:40:35 GMT 2025
|
PRIMARY |